Recombinant Human SLAMF7 (C-mFc)

Description

EnkiLife provides the Recombinant Human SLAMF7 (C-mFc) protein,aslo know as SLAM Family Member 7,CD2 Subset 1,CD2-Like Receptor-Activating Cytotoxic Cells,CRACC,Membrane Protein FOAP-12,Novel Ly9,Protein 19A,CD319,SLAMF7,CS1, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human SLAM Family Member 7 is produced by our Mammalian expression system and the target gene encoding Ser23-Met226 is expressed with a mouse IgG1 Fc tag at the C-terminus.Accession:Q9NQ25. Expression Host:Human Cells.Species:Human .Predicted Molecular Mass:49 KDa. Background:SLAMF7 is a single-pass type I membrane protein and contains 1 Ig-like C2-type (immunoglobulin-like) domain. SLAMF7 is expressed in NK cells, activated B-cells, NK-cell line but not in promyelocytic, B-cell lines, or T-cell lines. Although the cytoplasmic domain of CS1 contains immunoreceptor tyrosine-based switch motifs (ITSM), which enables to recruite signaling lymphocyte activation molecule (SLAM)-associated protein (SAP/SH2D1A), it activates NK cells in the absence of a functional SAP. SLAMF7 positively regulated natural killer cell functions by a mechanism dependent on the adaptor EAT-2 but not the related adaptor SAP. However, in the absence of EAT-2, CRACC potently inhibited natural killer cell function. It was also inhibitory in T cells, which are typically devoid of EAT-2. Thus, SLAMF7 can exert activating or inhibitory influences on cells of the immune system depending on cellular context and the availability of effector proteins.